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Letters to the Editor
Parkinson's Disease and Bone Health SIR-We were very interested in the paper by Abou-Raya et al.
[1] regarding bone health and Parkinson's disease. In our rural community of Ceredigion, West Wales, we carried out a similar study in 2007. We were prompted by a spate of hip fractures amongst our patients attending the movement disorder clinic. We looked at 50 patients (31 males) and enrolled their carers as controls for vitamin D levels. We excluded those with other causes for osteoporosis and whilst we did not perform spinal radiology to look for occult vertebral fracture, we did collect data on known fractures in the patient group. Our data were presented in poster form at the National Osteoporosis Society meeting in 2007. Five of our patient group had a prevalent fragility fracture (four females). Four of the group (three males) had osteoporosis at the femoral neck (T score <−2.5) and six (four males) had vertebral osteoporosis. Forty patients (29 males) had insufficient vitamin D as defined by a vitamin D level of <30 ng/ml. We found a weak correlation between bone health and Hoehn and Yahr score (r = −0.32, P = 0.06).
We also found that 32 of 41 carers had vitamin D levels <30 ng/ml.
As a consequence of our findings and published data relating to bone health in movement disorder patients, we now perform dual energy X-ray absorptiometry scan at diagnosis and at two yearly intervals thereafter. Experience tells us that patients with movement disorder fare poorly after major fragility fracture and we need to do all we can to reduce this risk whilst there is time to do so.
Time will tell if we have been able to reduce the risk of fragility fracture in this vulnerable population, and we are gratified to find other centres recommending the same approach! Powerful pancreatic digestive enzymes may cause destruction of body tissues if their compartmentalisation in the lumen of the intestine and pancreas is compromised. If such enzymes damage the intestinal wall or if the tight junctions making up the intestinal mucosal barrier are disrupted, uncontrolled degrading activity in the plasma would cause proteolytic cleavage of the extracellular domain of membrane receptors and loss of associated cellular functions. Proteolytic cleavage of the insulin receptor would cause inability of insulin to signal glucose across the cellular membrane [2] .
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